@boehringerglobal.bsky.social
Join the conversation on the latest in healthcare innovation for humans and animals. #LifeForward
Imprint: https://www.boehringer-ingelheim.com/imprint
Privacy notice: https://www.boehringer-ingelheim.com/privacy-notice
@boehringerglobal.bsky.social#NEWS: Phase III trial data for people living with #obesity, overweight & #T2D were presented today at @easdnews.bsky.social
These results will help us understand how survodutide can provide weight loss benefits whilst improving blood sugar levels.
@boehringerglobal.bsky.social#NEWS: We have launched a new Stop Rabies project in Zimbabwe together with AWARE. By combining dog vaccination, population management and community education, we aim to help reduce the burden of rabies in Tsholotsho District and protect both people & animals.
@boehringerglobal.bsky.social#News: We’re launching SCOVELLA® in GB, the first licensed therapy to treat hyperinsulinaemia in insulin-dysregulated horses. It addresses the main cause of laminitis, one of the most devastating diseases affecting horses.
